By Mrinalika Roy

(Reuters) -AstraZeneca and Daiichi Sankyo’s drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

The findings from both trials, presented at the European Society for Medical Oncology Congress, indicate that the drug, currently used for advanced stages of certain cancers, could advance toward curative treatment.

In one late-stage study, Enhertu cut the risk of invasive disease recurrence or death by 53% compared with Roche’s Kadcyla, in patients with high-risk early HER2-positive breast cancer that persisted after surgery and initial therapy.

Three years after treatment, 92.4% of patients on Enhertu were alive and disease-free, versus 83.7% on Kadcyla.

Enhertu belong

See Full Page